Show simple item record

Role of the CD28 receptor in T-cell activation

dc.contributor.authorJune, Carl H.en_US
dc.contributor.authorLedbetter, Jeffrey A.en_US
dc.contributor.authorLinsley, Peter S.en_US
dc.contributor.authorThompson, Craig B.en_US
dc.date.accessioned2006-04-10T13:54:41Z
dc.date.available2006-04-10T13:54:41Z
dc.date.issued1990en_US
dc.identifier.citationJune, Carl H., Ledbetter, Jeffrey A., Linsley, Peter S., Thompson, Craig B. (1990)."Role of the CD28 receptor in T-cell activation." Immunology Today 11(): 211-216. <http://hdl.handle.net/2027.42/28838>en_US
dc.identifier.urihttp://www.sciencedirect.com/science/article/B6VHW-4847DBJ-49/2/8203f5b041926a7b0be66e5fec9d1554en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/28838
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2162180&dopt=citationen_US
dc.description.abstractAntigen-specific T-cell activation is initiated through the T-cell receptor. Recent evidence has shown that a number of additional T-cell surface receptors serve to regulate the responses of antigen-activated T cells. One such molecule, CD28, is a member of a heterophilic cell adhesion complex, and is the receptor for the B-cell-restricted B7/BB-1 antigen. As Carl June, Jeffrey Ledbetter, Peter Linsley and Craig Thompson review here, CD28 serves as the surface component of a novel signal transduction pathway that modulates T-cell lymphokine production and increases the resistance of cell responses to various immunosuppressive agents.en_US
dc.format.extent987446 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherElsevieren_US
dc.titleRole of the CD28 receptor in T-cell activationen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumHoward Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USAen_US
dc.contributor.affiliationotherNaval Medical Research Institute, Bethesda, MD 20814, USAen_US
dc.contributor.affiliationotherOncogen Corp., Seattle, WA 98121, USAen_US
dc.contributor.affiliationotherOncogen Corp., Seattle, WA 98121, USAen_US
dc.identifier.pmid2162180en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/28838/1/0000673.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1016/0167-5699(90)90085-Nen_US
dc.identifier.sourceImmunology Todayen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.